These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 18070979

  • 1. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
    Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J.
    Antimicrob Agents Chemother; 2008 Feb; 52(2):539-50. PubMed ID: 18070979
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.
    Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D.
    Antimicrob Agents Chemother; 2004 Jan; 48(1):137-42. PubMed ID: 14693531
    [Abstract] [Full Text] [Related]

  • 3. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
    Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J.
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
    [Abstract] [Full Text] [Related]

  • 4. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.
    Andes D, Marchillo K, Stamstad T, Conklin R.
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1193-9. PubMed ID: 12654646
    [Abstract] [Full Text] [Related]

  • 5. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
    Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.
    Lepak AJ, Zhao M, Andes DR.
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481440
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
    Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW.
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
    Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D.
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
    [Abstract] [Full Text] [Related]

  • 18. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [Abstract] [Full Text] [Related]

  • 19. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
    Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ.
    J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
    [Abstract] [Full Text] [Related]

  • 20. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
    Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing.
    Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.